Allergan, Inc.

Evelyn G Corpuz

Ken Chow

Wenkui Ken Fang

Liming Wang

Wha-Bin Im

Santosh C Sinha

Daniel W Gil

Wha Bin Im

Michael E Garst

Smita S Bhat

John E Donello

Mohammad I Dibas

Todd M Heidelbaugh

Phong X Nguyen

Ling Li

Janet A Takeuchi

Mohammed I Dibas

Wenkiu K Fang

Compounds are described herein useful for treating diseases and conditions by modulation of one or more alpha adrenergic receptor. The compounds can include a naphthalene, a quinoline, a benzimidazole or an isoquinoline as a core structure. Methods of making, using and formulating these compounds are described.

Alpha adrenergic receptor modulators

Compounds are described herein useful for treating diseases and conditions by modulation of one or more alpha adrenergic receptor. The compounds can include a naphthalene, a quinoline, a benzoimidazole or an isoquinoline as a core structure. Methods of making, using and formulating these compounds are described.

The present invention relates to novel azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.

Azetidine derivatives as sphingosine 1-phosphate (S1P) receptor modulators

The present invention relates to alkene azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.

Alkene azetidine derivatives as sphingosine 1-phosphate (S1P) receptor modulators

The present invention relates to novel oxadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.

Oxadiazole derivatives as sphingosine 1-phosphate (S1P) receptor modulators

The present invention relates to novel phenoxy derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.

Phenoxy derivatives as sphingosine 1-phosphate (S1P) receptor modulators

The present invention relates to novel benzyl azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.

Benzyl azetidine derivatives as sphingosine 1-phosphate (S1P) receptor modulators

The invention provides compounds represented by the formula I, each of which compounds may have sphingosine-1-phosphate receptor agonist and or antagonist biological activity, wherein these compounds selected from the group consisting of wherein A, B, C, D, X, Y, Z and Rare defined in the specification. Said compounds are useful for treating a disease or condition of a mammal selected from the group consisting of ocular diseases; systemic vascular barrier related diseases; allergies and other inflammatory diseases; cardiac diseases or conditions; fibrosis; pain and wounds.

[object Object]

The present invention relates to novel pyridine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.

Pyridine derivatives as sphingosine 1-phosphate (S1P) receptor modulators

The present invention relates to novel phenoxy-azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.

Phenoxy-azetidine derivatives as sphingosine 1-phosphate (S1P) receptor modulators

The present invention relates to novel oxime derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.

Oxime derivatives as sphingosine 1-phosphate (S1P) receptor modulators

The invention provides well-defined aryl fluoroethyl ureas that are useful as selective alphaadrenergic agonists. As such, the compounds described herein are useful in treating a wide variety of disorders associated with modulation of alphaadrenergic receptors.

Growing community of inventors

Irvine, CA, United States of America

Evelyn G Corpuz